Evaluating new healthcare technologies in cancer

评估癌症领域的新医疗保健技术

• 批准号: MC_UU_00004/01
• 负责人: Mahesh Parmar
• 金额: $ 660.8万
• 依托单位: University College London
• 依托单位国家: 英国
• 项目类别: Intramural
• 财政年份: 2021
• 资助国家: 英国
• 起止时间: 2021 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=MC_UU_00004%2F01
• 关键词: Evaluating; new; healthcare; technologies; cancer

Our aim is to reduce cancer deaths and the side effects associated with cancer treatments. We design clinical trials and other research studies that test several new approaches at the same time. This speeds up the evaluation of new therapies. In this programme we focus on new scientific developments. In particular new drugs that target cancers that have specific genetic markers, as well as drugs that prevent a cancer’s blood vessels developing. Cancers need new blood vessels to survive and grow. We are also testing the new immuno-oncology drugs. These drugs help the bodies’ immune system kill cancer cells. We will also test other new technologies such as artificial intelligence to improve cancer treatments. Artificial intelligence uses a computer’s power to do tasks that normally require human input. For example radiotherapy (x-ray treatment) can be used to cure cancers. But it is a complex and time consuming process to plan the treatment. It is important that the radiotherapy only targets the cancer and doesn’t harm healthy tissue near the cancer. Using a computer to speed up this process would potentially allow many more patients to be treated sooner. This could be used in countries all over the world. In our studies we collect blood samples from participants and work with laboratory scientists and industry partners to provide more knowledge about how cancers develop and grow. Where possible we use this information in our future studies.

我们的目标是减少癌症死亡和与癌症治疗相关的副作用。我们设计临床试验和其他研究，同时测试几种新方法。这加快了对新疗法的评估。 在这个项目中，我们专注于新的科学发展。特别是针对具有特定遗传标记的癌症的新药，以及防止癌症血管发展的药物。癌症需要新的血管才能生存和生长。我们还在测试新的免疫肿瘤药物。这些药物帮助人体的免疫系统杀死癌细胞。我们还将测试其他新技术，如人工智能，以改善癌症治疗。人工智能利用计算机的能力来完成通常需要人工输入的任务。例如，放射疗法（X射线治疗）可用于治愈癌症。但是，计划治疗是一个复杂而耗时的过程。重要的是，放射治疗只针对癌症，不伤害癌症附近的健康组织。使用计算机来加快这一过程可能会让更多的患者更快地得到治疗。这可以在世界各国使用。在我们的研究中，我们收集了参与者的血液样本，并与实验室科学家和行业合作伙伴合作，提供更多关于癌症如何发展和生长的知识。在可能的情况下，我们将在未来的研究中使用这些信息。

项目成果

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.

• DOI: 10.1016/s0140-6736(21)02437-5
• 发表时间: 2022-01-29
• 期刊: Lancet (London, England)
• 作者: Attard G;Murphy L;Clarke NW;Cross W;Jones RJ;Parker CC;Gillessen S;Cook A;Brawley C;Amos CL;Atako N;Pugh C;Buckner M;Chowdhury S;Malik Z;Russell JM;Gilson C;Rush H;Bowen J;Lydon A;Pedley I;O'Sullivan JM;Birtle A;Gale J;Srihari N;Thomas C;Tanguay J;Wagstaff J;Das P;Gray E;Alzoueb M;Parikh O;Robinson A;Syndikus I;Wylie J;Zarkar A;Thalmann G;de Bono JS;Dearnaley DP;Mason MD;Gilbert D;Langley RE;Millman R;Matheson D;Sydes MR;Brown LC;Parmar MKB;James ND;Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators
• 通讯作者: Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators

Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.

• DOI: 10.1001/jamaoncol.2020.7857
• 发表时间: 2021-04-01
• 期刊: JAMA oncology
• 影响因子: 28.4
• 作者: Ali A;Hoyle A;Haran ÁM;Brawley CD;Cook A;Amos C;Calvert J;Douis H;Mason MD;Dearnaley D;Attard G;Gillessen S;Parmar MKB;Parker CC;Sydes MR;James ND;Clarke NW
• 通讯作者: Clarke NW

Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial.

• DOI: 10.1200/jco.21.01436
• 发表时间: 2021-11-20
• 期刊: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
• 作者: Adams RA;Fisher DJ;Graham J;Seligmann JF;Seymour M;Kaplan R;Yates E;Parmar M;Richman SD;Quirke P;Butler R;Brown E;Collinson F;Falk S;Wasan H;Shiu KK;Middleton G;Samuel L;Wilson RH;Brown LC;Maughan TS;FOCUS4 Trial Investigators
• 通讯作者: FOCUS4 Trial Investigators

Common variants in breast cancer risk loci predispose to distinct tumor subtypes.

• DOI: 10.1186/s13058-021-01484-x
• 发表时间: 2022-01-04
• 期刊: Breast cancer research : BCR
• 作者: Ahearn TU;Zhang H;Michailidou K;Milne RL;Bolla MK;Dennis J;Dunning AM;Lush M;Wang Q;Andrulis IL;Anton-Culver H;Arndt V;Aronson KJ;Auer PL;Augustinsson A;Baten A;Becher H;Behrens S;Benitez J;Bermisheva M;Blomqvist C;Bojesen SE;Bonanni B;Børresen-Dale AL;Brauch H;Brenner H;Brooks-Wilson A;Brüning T;Burwinkel B;Buys SS;Canzian F;Castelao JE;Chang-Claude J;Chanock SJ;Chenevix-Trench G;Clarke CL;NBCS Collaborators;Collée JM;Cox A;Cross SS;Czene K;Daly MB;Devilee P;Dörk T;Dwek M;Eccles DM;Evans DG;Fasching PA;Figueroa J;Floris G;Gago-Dominguez M;Gapstur SM;García-Sáenz JA;Gaudet MM;Giles GG;Goldberg MS;González-Neira A;Alnæs GIG;Grip M;Guénel P;Haiman CA;Hall P;Hamann U;Harkness EF;Heemskerk-Gerritsen BAM;Holleczek B;Hollestelle A;Hooning MJ;Hoover RN;Hopper JL;Howell A;ABCTB Investigators;kConFab/AOCS Investigators;Jakimovska M;Jakubowska A;John EM;Jones ME;Jung A;Kaaks R;Kauppila S;Keeman R;Khusnutdinova E;Kitahara CM;Ko YD;Koutros S;Kristensen VN;Krüger U;Kubelka-Sabit K;Kurian AW;Kyriacou K;Lambrechts D;Lee DG;Lindblom A;Linet M;Lissowska J;Llaneza A;Lo WY;MacInnis RJ;Mannermaa A;Manoochehri M;Margolin S;Martinez ME;McLean C;Meindl A;Menon U;Nevanlinna H;Newman WG;Nodora J;Offit K;Olsson H;Orr N;Park-Simon TW;Patel AV;Peto J;Pita G;Plaseska-Karanfilska D;Prentice R;Punie K;Pylkäs K;Radice P;Rennert G;Romero A;Rüdiger T;Saloustros E;Sampson S;Sandler DP;Sawyer EJ;Schmutzler RK;Schoemaker MJ;Schöttker B;Sherman ME;Shu XO;Smichkoska S;Southey MC;Spinelli JJ;Swerdlow AJ;Tamimi RM;Tapper WJ;Taylor JA;Teras LR;Terry MB;Torres D;Troester MA;Vachon CM;van Deurzen CHM;van Veen EM;Wagner P;Weinberg CR;Wendt C;Wesseling J;Winqvist R;Wolk A;Yang XR;Zheng W;Couch FJ;Simard J;Kraft P;Easton DF;Pharoah PDP;Schmidt MK;García-Closas M;Chatterjee N
• 通讯作者: Chatterjee N